IP Library Granted Patent US 8,722,917
Granted Patent B2
US 8,722,917 · App. 13/356,488 · Granted May 13, 2014

Boron-containing small molecules

Inventors: Stephen J. Baker (Mountain View, CA); Tsutomu Akama (Sunnyvale, CA); Michael Richard Kevin Alley (Santa Clara, CA); Stephen J. Benkovic (College, PA); Michael Dipierro (Wadsworth, IL); Vincent S. Hernandez (Watsonville, CA); Karin M. Hold (Belmont, CA); Isaac Kennedy (Bollingbrook, IL); Igor Likhotvorik (Morton Grove, IL); Weimin Mao (Sunnyvale, CA); Kirk Maples (San Jose, CA); Jacob J. Plattner (Orinda, CA); Fernando Rock (Los Altos, CA); Virginia Sanders (San Francisco, CA); Aaron M. Stemphoski (Florence, SC); George Petros Yiannikouros (Florence, SC); Siead Zagar (Orlando Park, IL); Yong-Kang Zhang (San Jose, CA); Huchen Zhou (Shanghai, CN)
Assignee: Anacor Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,917
App. No.
13/356,488
Granted
May 13, 2014
Kind
B2
Abstract

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Claims (52)

1. A compound, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:

in which

R 1 and R 2 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

wherein R 1 and R 2 , together with the atoms to which they are attached, can be optionally joined to form a 4- to 7-membered ring;

Z1 is a member selected from

wherein

R 3a and R 4a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R 5 is a member selected from halogen and OR 8

wherein

R 8 is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, unsubstituted aryl, and substituted or unsubstituted heteroaryl

R 9a is H, R 11a is H, R 12a is H, and R 10a is halogen.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl

and wherein R 1 and R 2 , together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane and substituted or unsubstituted dioxaborepane.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 , together with the atoms to which they are joined, form a member selected from dioxaborolane, substituted or unsubstituted tetramethyldioxaborolane, substituted or unsubstituted phenyldioxaborolane, dioxaborinane, dimethyldioxaborinane and dioxaborepane.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z1 is

and R 5 is substituted or unsubstituted tetrahydro-2H-pyran-2-yloxy.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 3a is H and R 4a is a member selected from methyl, ethyl, propyl, butyl, phenyl, benzyl and cyano.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 10a is a member selected from the group consisting of fluoro, chloro, and bromo.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from

9. A compound, or a pharmaceutically acceptable salt thereof, having a structure according to the formula:

in which

X is a member selected from substituted or unsubstituted triflate, halogen, substituted or unsubstituted sulfonic esters and substituted or unsubstituted acyloxy groups, and substituted or unsubstituted diazo;

R 1 and R 2 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. R 1 and R 2 , together with the atoms to which they are attached, can be optionally joined to form a 4- to 7-membered ring;

R 3a and R 4a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R 9a , R 10a , R 11a and R 12a are members independently selected from H, OR*, NR*R**, SR*, —S(O)R*, —S(O) 2 R*, —S(O) 2 NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

wherein each R* and R* * are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl

with the proviso that that the compound is not:

10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstitutcd isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl

and wherein R 1 and R 2 , together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane and substituted or unsubstituted dioxaborepane.

11. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 , together with the atoms to which they are joined, form a member selected from dioxaborolane, substituted or unsubstituted tetramethyldioxaborolane, substituted or unsubstituted phenyldioxaborolane, dioxaborinane, dimethyldioxaborinane and dioxaborepane.

12. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said X is a member selected from triflate, chloro, bromo, iodo, substituted or unsubstituted sulfonic esters, substituted or unsubstituted acyloxy groups, and substituted or unsubstituted diazo.

13. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said R 3a is H and R 4a is a member selected from methyl, ethyl, propyl, butyl, phenyl, benzyl and cyano.

14. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 9a is H, R 11a is H, R 12a is H, R 10a is a member selected from the group consisting of halogen, cyano, nitro, substituted or unsubstituted methoxy, substituted or unsubstituted methyl, substituted or unsubstituted ethoxy, substituted or unsubstituted ethyl, trifluoromethyl, substituted or unsubstituted hydroxymethyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted benzyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenyloxy, substituted or unsubstituted phenyl methoxy, substituted or unsubstituted thiophenyloxy, substituted or unsubstituted pyridinyloxy, substituted or unsubstituted pyrimidinyloxy, substituted or unsubstituted benzylfuran, substituted or unsubstituted methylthio, substituted or unsubstituted mercaptomethyl, substituted or unsubstituted mercaptoalkyl, substituted or unsubstituted phenylthio, substituted or unsubstituted thiophenylthio, substituted or unsubstituted phenyl methylthio, substituted or unsubstituted pyridinylthio, substituted or unsubstituted pyrimidinylthio, substituted or unsubstituted benzylthiofuranyl, substituted or unsubstituted phenylsulfonyl, substituted or unsubstituted benzylsulfonyl, substituted or unsubstituted phenylmethylsulfonyl, substituted or unsubstituted thiophenylsulfonyl, substituted or unsubstituted pyridinylsulfonyl, substituted or unsubstituted pyrimidinylsulfonyl, substituted or unsubstituted sulfonamidyl, substituted or unsubstituted phenylsulfinyl, substituted or unsubstituted benzylsulfinyl, substituted or unsubstituted phenylmethylsulfinyl, substituted or unsubstituted thiophenylsulfinyl, substituted or unsubstituted pyridinylsulfinyl, substituted or unsubstituted pyrimidinylsulfinyl, substituted or unsubstituted amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted trifluoromethylamino, substituted or unsubstituted aminomethyl, substituted or unsubstituted alkylaminomethyl, substituted or unsubstituted dialkylaminomethyl, substituted or unsubstituted arylaminomethyl, substituted or unsubstituted benzylamino, substituted or unsubstituted phenylamino, substituted or unsubstituted thiophenylamino, substituted or unsubstituted pyridinylamino, substituted or unsubstituted pyrimidinylamino, substituted or unsubstituted indolyl, substituted or unsubstituted morpholino, substituted or unsubstituted alkylamido, substituted or unsubstituted arylamido, substituted or unsubstituted ureido, substituted or unsubstituted carbamoyl, and substituted or unsubstituted piperizinyl.

15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof, wherein R 10a is a member selected from the group consisting of fluoro, chloro, bromo, nitro, cyano, amino, methyl, hydroxylmethyl, trifluoromethyl, methoxy, trifluoromethyoxy, ethyl, diethylcarbamoyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidinyl, piperizino, piperizinyl, piperizinocarbonyl, piperizinylcarbonyl, carboxyl, 1-tetrazolyl, 1-ethoxycarbonylmethoxy, carboxymethoxy, thiophenyl, 3-(butylcarbonyl)phenylmethoxy, 1H-tetrazol-5-yl, 1-ethoxycarbonylmethyloxy-, 1-ethoxycarbonylmethyl-, 1-ethoxycarbonyl-, carboxymethoxy-, thiophen-2-yl, thiophen-2-ylthio-, thiophen-3-yl, thiophen-3-ylthio, 4-fluorophenylthio, butylcarbonylphenylmethoxy, butylcarbonylphenylmethyl, butylcarbonylmethyl, 1-(piperidin-1-yl)carbonyl)methyl, 1-(piperidin-1-yl)carbonyl)methoxy, 1-(piperidin-2-yl)carbonyl)methoxy, 1-(piperidin-3-yl)carbonyl)methoxy, 1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl)methoxy, 1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl)methyl, 1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl, 1-4-(pyrimidin-2-yl)piperazin-1-yl, 1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl), 1-(4-(pyridin-2-yl)piperazin-1-yl)carbonylmethyl, (1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl)-methoxy), 1-(4-(pyridin-2-yl)piperazin-1-yl, 1H-indol-1-yl, morpholino-, morpholinyl, morpholinocarbonyl, morpholinylcarbonyl, phenylureido, phenylcarbamoyl, acetamido, 3-(phenylthio)-1H-indol-1-yl, 3-(2-cyanoethylthio)-1H-indol-1-yl, benzylamino, 5-methoxy-3-(phenylthio)-1H-indol-1-yl, 5-methoxy-3-(2-cyanoethylthio)-1H-indol-1-yl)), 5-chloro-1H-indol-1-yl, 5-chloro-3-(2-cyanoethylthio)-1H-indol-1-yl)), dibenzylamino, benzylamino, 5-chloro-3-(phenylthio)-1H-indol-1-yl)), 4-(1H-tetrazol-5-yl)phenoxy, 4-(1H-tetrazol-5-yl)phenyl, 4-(1H-tetrazol-5-yl)phenylthio, 2-cyanophenoxy, 3-cyanophenoxy, 4-cyanophenoxy, 2-cyanophenylthio, 3-cyanophenylthio, 4-cyanophenylthio, 2-chlorophenoxy, 3-chlorophenoxy, 4-chlorophenoxy, 2-fluorophenoxy, 3-fluorophenoxy, 4-fluorophenoxy, 2-cyanobenzyloxy, 3-cyanobenzyloxy, 4-cyanobenzyloxy, 2-chlorobenzyloxy, 3-chlorobenzyloxy, 4-chlorobenzyloxy, 2-fluorobenzyloxy, 3-fluorobenzyloxy, and 4-fluorobenzyloxy.

16. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from

17. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from:

18. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from:

19. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl.

20. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are each members independently selected from R 1 and R 2 , together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane, substituted or unsubstituted dioxaborepane.

21. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said X is a sulfonic ester group which is selected from the group consisting of substituted or unsubstituted mesylate, substituted or unsubstituted tosylate, substituted or unsubstituted brosylate and substituted or unsubstituted nosylate.

22. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said X is an acyloxy group which is substituted or unsubstituted acetoxy or substituted or unsubstituted trifluoroacetoxy.

23. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said X is selected from the group consisting of bromo, iodo, mesylate and diazo.

24. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said X is bromo or iodo.

25. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein said compound is

26. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 2 are each members independently selected from H, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, phenyl and benzyl.

27. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are each members independently selected from H, methyl, isopropyl, and phenyl.

28. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are methyl.

29. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are isopropyl.

30. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said R 1 and said R 2 are H.

31. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having a structure according to the following formula:

32. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from

Assignments (2)
CHANGE OF NAME Recorded Jul 13, 2023
From: ANACOR PHARMACEUTICALS, INC.
To: ANACOR PHARMACEUTICALS, LLC
Reel/Frame 064272/0688 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2012
From: BAKER, STEPHEN J.; AKAMA, TSUTOMU; ALLEY, MICHAEL RICHARD KEVIN; BENKOVIC, STEPHEN J.; DIPIERRO, MICHAEL; HERNANDEZ, VINCENT S.; HOLD, KARIN H.; KENNEDY, ISAAC; LIKHOTVORIK, IGOR; MAO, WEIMIN; MAPLES, KIRK R.; PLATTNER, JACOB J.; ROCK, FERNANDO; SANDERS, VIRGINIA; STEMPHOSKI, AARON M.; YIANNIKOUROS, GEORGE PETROS; ZEGAR, SIEAD; ZHANG, YONG-KANG; ZHOU, HUCHEN
To: ANACOR PHARMACEUTICALS, INC.
Reel/Frame 027761/0780 →
Continuity (8)
Continuation 12629753 · Dec 2, 2009
Division 11505591 · Aug 16, 2006
Division 13356488
Continuation In Part 11357687 · Feb 16, 2006
Provisional Application 60755227 · Dec 30, 2005
Provisional Application 60746361 · May 3, 2006
Provisional Application 60654060 · Feb 16, 2005
Related Publication 20120289686A1 · Nov 15, 2012